Details

Autor(en) / Beteiligte

• DIAMOND, Joshua M
• LEE, James C
• BHORADE, Sangeeta M
• CRESPO, Maria
• DEMISSIE, Ejigayehu
• SONETT, Joshua
• WILLE, Keith
• ORENS, Jonathan
• SHAH, Ashish S
• WEINACKER, Ann
• ARCASOY, Selim
• SHAH, Pali D
• KAWUT, Steven M
• WILKES, David S
• WARE, Lorraine B
• PALMER, Scott M
• CHRISTIE, Jason D
• SHAH, Rupal J
• RUSSELL LOCALIO, A
• BELLAMY, Scarlett L
• LEDERER, David J
• CANTU, Edward
• KOHL, Benjamin A
• LAMA, Vibha N

Titel

Clinical Risk Factors for Primary Graft Dysfunction after Lung Transplantation

Ist Teil von

• American journal of respiratory and critical care medicine, 2013-03, Vol.187 (5), p.527-534

Ort / Verlag

New York, NY: American Thoracic Society

Erscheinungsjahr

2013

Quelle

MEDLINE

Beschreibungen/Notizen

• Primary graft dysfunction (PGD) is the main cause of early morbidity and mortality after lung transplantation. Previous studies have yielded conflicting results for PGD risk factors. We sought to identify donor, recipient, and perioperative risk factors for PGD. We performed a 10-center prospective cohort study enrolled between March 2002 and December 2010 (the Lung Transplant Outcomes Group). The primary outcome was International Society for Heart and Lung Transplantation grade 3 PGD at 48 or 72 hours post-transplant. The association of potential risk factors with PGD was analyzed using multivariable conditional logistic regression. A total of 1,255 patients from 10 centers were enrolled; 211 subjects (16.8%) developed grade 3 PGD. In multivariable models, independent risk factors for PGD were any history of donor smoking (odds ratio [OR], 1.8; 95% confidence interval [CI], 1.2-2.6; P = 0.002); FiO2 during allograft reperfusion (OR, 1.1 per 10% increase in FiO2; 95% CI, 1.0-1.2; P = 0.01); single lung transplant (OR, 2; 95% CI, 1.2-3.3; P = 0.008); use of cardiopulmonary bypass (OR, 3.4; 95% CI, 2.2-5.3; P < 0.001); overweight (OR, 1.8; 95% CI, 1.2-2.7; P = 0.01) and obese (OR, 2.3; 95% CI, 1.3-3.9; P = 0.004) recipient body mass index; preoperative sarcoidosis (OR, 2.5; 95% CI, 1.1-5.6; P = 0.03) or pulmonary arterial hypertension (OR, 3.5; 95% CI, 1.6-7.7; P = 0.002); and mean pulmonary artery pressure (OR, 1.3 per 10 mm Hg increase; 95% CI, 1.1-1.5; P < 0.001). PGD was significantly associated with 90-day (relative risk, 4.8; absolute risk increase, 18%; P < 0.001) and 1-year (relative risk, 3; absolute risk increase, 23%; P < 0.001) mortality. We identified grade 3 PGD risk factors, several of which are potentially modifiable and should be prioritized for future research aimed at preventative strategies. Clinical trial registered with www.clinicaltrials.gov (NCT 00552357).